Buy, Sell or Hold: Vertex Pharmaceuticals Inc. (VRTX-Q)

Home Daily Stock Opinions and Ratings Vertex Pharmaceuticals Inc. (VRTX-Q)

NASDAQ:VRTX

349.53

4.75 (1.34%) 1d

PARTIAL SELL

A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 72.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. To be disciplined, we recommend trailing up the stop (from $320) to $330 at this time.

Pharma & Healthcare

BUY

Not too expensive. They report next week. They have good momentum and products.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 71.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. We now recommend to trail up the stop (from $300) to $320.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 03/23, Up 57.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well. We recommend trailing up the stop to $300 at this time.

Pharma & Healthcare

BUY

New for him. Are diversifying away from Cystic Fibrosis drugs into other treatments.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 34.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $270) to $280.

Pharma & Healthcare

TOP PICK

It is in the biotech sector which came under pressure18 months ago. The sector found a footing in June and has held well above lows while the market is selling off. In general there are great bio technologies coming to market. Specifically it is a leading producer of a Cystic Fibrosis treatment that continues to proliferate around global health care systems. It is head and shoulders over what was available previously. It is a defensive stock because earnings are not cyclical and it is growing at 25% per year as well as trading at 18X next year's earnings. With a 74 billion market cap it just made a 5 year high which is very significant. (Analysts’ price target is $310.80)

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 29.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK is progressing well. We now recommend trailing up the stop (from $245) to $270.

Pharma & Healthcare

BUY

Bought this, adding to his healthcare holdings, a defensive sector he likes. Strong balance sheet with a deep pipeline of drugs, 20x 2023 earnings, 50% operating margins, and 5% free cash flow yield.

Pharma & Healthcare

TOP PICK

Biotech. Dominant drug for CF treatment. Exceedingly strong growth profile, with 2022 estimate for 40% earnings growth. Working on a compound for acute pain that's not addictive. Technically way outperformed the biotech group. Now there's strength in the group and the market. No dividend. (Analysts’ price target is $307.75)

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 21%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $230) to $245.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 16.4%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with VRTX has achieved its $258 objective. To remain disciplined, we recommend covering half the position here and trailing up the stop (from $220) to $230.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 21.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. We now recommend trailing up the stop (from $200) to $220.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly We again reiterate this long known developer of treatment for cystic fibrosis as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases such as Type I diabetes and muscular dystrophy. Recently reported earnings beat analyst expectations by 30% and the company maintains a ROE of 31%. We also like how the company has continued to increase cash reserves, while buying back stock. We recommend trailing up the stop (from $185) to $200, looking to achieve $258 -- upside potential over 16%. Yield 0% (Analysts’ price target is $257.41)

Pharma & Healthcare

Showing 1 to 15 of 21 entries

Vertex Pharmaceuticals Inc.(VRTX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 8

Stockchase rating for Vertex Pharmaceuticals Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Vertex Pharmaceuticals Inc.(VRTX-Q) Frequently Asked Questions

What is Vertex Pharmaceuticals Inc. stock symbol?

Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q

Is Vertex Pharmaceuticals Inc. a buy or a sell?

In the last year, 8 stock analysts published opinions about VRTX-Q. 7 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..

Is Vertex Pharmaceuticals Inc. a good investment or a top pick?

Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..

Why is Vertex Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Vertex Pharmaceuticals Inc. worth watching?

8 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.

What is Vertex Pharmaceuticals Inc. stock price?

On 2023-09-22, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $349.53.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Trending stocks today

Vertex Pharmaceuticals Inc. (VRTX-Q)

NASDAQ:VRTX

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

Vertex Pharmaceuticals Inc.(VRTX-Q)

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Vertex Pharmaceuticals Inc.(VRTX-Q)

Vertex Pharmaceuticals Inc.(VRTX-Q) Rating

Vertex Pharmaceuticals Inc.(VRTX-Q) Frequently Asked Questions

What is Vertex Pharmaceuticals Inc. stock symbol?

Is Vertex Pharmaceuticals Inc. a buy or a sell?

Is Vertex Pharmaceuticals Inc. a good investment or a top pick?

Why is Vertex Pharmaceuticals Inc. stock dropping?

Is Vertex Pharmaceuticals Inc. worth watching?

What is Vertex Pharmaceuticals Inc. stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Gordon Reid

Stockchase Insights

Stephen Weiss, Founder, Short Hills Capital Partners

Bryn Talkington

Shannon Saccocia, CIO, Boston Private